.Pharmacolibrary.Drugs.ATC.L.L01XX67

Information

name:Tagraxofusp
ATC code:L01XX67
route:intravenous
compartments:2
dosage:12mg
volume of distribution:6.5L
clearance:2.5L/h
other parameters in model implementation

Tagraxofusp (SL-401) is a fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp is approved for adult and pediatric patients 2 years and older with BPDCN.

Pharmacokinetics

Pharmacokinetics in adult patients with BPDCN, after intravenous infusion. Values primarily reflect population PK analyses from clinical studies.

References

    Revisions


    Generated at 2025-08-11T18:21:04Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos